Jacobs Engineering Group
J
$150.62
-2.56%
Jacobs Solutions Inc. is a global professional services firm providing engineering, design, procurement, construction management, and cyber/security consulting to industrial, commercial, and government clients across water, transportation, healthcare, technology, and chemicals end markets, generating roughly $12 billion in fiscal 2025 revenue with approximately 43,000 employees. The company is a scaled, blue-chip player in the Engineering & Construction sector, distinguished by a consulting-heavy, asset-light model and a large backlog tied to public infrastructure and advanced-facilities spending rather than commodity-style fixed-price construction risk. The current investor narrative centers on a sharp growth reacceleration — most recent quarterly revenue of $4.08 billion rose 34.6% year over year — alongside a volatile earnings profile (a Q2 FY26 net loss of $45.9 million followed by a Q3 rebound to $136.6 million), which has kept the debate focused on margin durability, the PA Consulting and Infrastructure & Advanced Facilities mix, and whether the recent run to near 52-week highs is justified by forward earnings power. With no fresh news headlines in the dataset, price action and the Q3 FY26 print (filed August 4, 2026) are the dominant drivers of sentiment.…
J
Jacobs Engineering Group
$150.62
Investment Opinion: Should I buy J Today?
Rating: Hold. Jacobs is a high-quality, asset-light engineering and consulting franchise whose revenue is reaccelerating (+34.6% YoY to $4.076 billion in Q3 FY26), but at $158.23 the stock already trades at 93% of its 52-week range with only +2.9% upside to the $162.80 consensus target, so the risk/reward is balanced rather than compelling. The core thesis is that the market has priced in the forward EPS recovery to $11.43 (19.21x forward PE) while gross margin has compressed for four straight quarters to 19.89%, leaving little margin of safety until the Q4 FY26 print proves operating leverage.
Supporting evidence is mixed but tilts toward patience rather than accumulation. On the positive side, revenue rose from $3.295 billion (Q1) to $3.695 billion (Q2) to $4.076 billion (Q3), PS of 1.48x and EV/Sales of 1.50x sit near the bottom of the multi-year band (versus 5.63x in Q4 FY25), TTM free cash flow of $644.5 million is a ~3.6% FCF yield, and the 10-Buy/6-Hold/0-Sell distribution with a $188 high target shows the Street still sees upside. Against that, Q3 EPS of $1.16 trails the prior-year $1.55 despite 34.6% more revenue, TTM net margin is just 2.41%, EV/EBITDA of 20.75x and P/B of 4.88x are premium-leaning, and the 61.87x trailing PE versus 19.21x forward embeds a dramatic earnings recovery that has yet to appear in margins.
The biggest risks that could invalidate even a neutral stance are continued gross-margin compression toward the high-teens, a Q4 FY26 EPS miss versus the $11.43 consensus that triggers downgrades from the 10-Buy bloc, and the lumpy cash profile (Q2 FY26 operating cash flow of -$484.1 million on a $501.1 million working-capital drain) combined with debt-to-equity of 0.744 and a current ratio of 1.301. This Hold would upgrade to Buy if gross margin stabilizes at or above 20% and the Q4 print validates forward EPS, pushing the stock toward the $188 high target; it would downgrade to Sell if gross margin breaks below 19% or forward EPS guidance is cut, opening the path to the $144 low target. Net verdict: fairly valued on forward earnings, cheap on sales, and expensive on current cash earnings — a stock to own on pullbacks toward the $144-$147 support zone rather than at the top of its range.
Sign up to view all
J 12-Month Price Forecast
Jacobs is a quality franchise in a genuine revenue reacceleration, but the stock has already captured the recovery with a +43.18% six-month run and now sits just 2.3% below its 52-week high with only 2.9% upside to the consensus target. The valuation is bifurcated: PS of 1.48x is near the bottom of its multi-year band while EV/EBITDA of 20.75x and P/B of 4.88x are premium-leaning, meaning the market is paying for an earnings inflection rather than current profitability. The decisive variable is gross margin — if it stabilizes near 20% and the $11.43 forward EPS materializes, the 19.21x forward PE is reasonable and the $188 high target is reachable; if compression continues toward the high-teens, the $144 low target comes into play. With beta of 0.669 limiting downside volatility but a 1-year relative strength of -8.99 points versus SPY showing the stock can lag, the risk/reward is balanced. I would upgrade to bullish on a Q4 FY26 print showing gross margin stabilization and EPS at or above consensus, and downgrade to bearish if gross margin breaks below 19% or forward guidance is cut.
Wall Street consensus
Coverage is solid with 15 analysts: 10 Buy, 6 Hold, and 0 Sell, a distribution that leans bullish but with a meaningful neutral bloc. The consensus average target price is $162.80, implying just +2.9% upside from the current $158.23 — a modest gap that suggests the stock has largely caught up to Street expectations after its +43.18% six-month run. Recent institutional actions are stable rather than directional: Citigroup reiterated Buy on October 23, KeyBanc reiterated Overweight on October 15, UBS reiterated Buy on August 10, and RBC reiterated Outperform on August 5, while Truist has stayed at Hold through multiple updates — a pattern of conviction-holding rather than fresh upgrades.
The target range of $144.00 to $188.00 is wide, spanning roughly -9.0% downside to +18.8% upside from spot, which signals genuine disagreement about the margin and earnings trajectory rather than a tight consensus. The $188 high target likely assumes gross margin stabilization, successful conversion of the 34.6% revenue growth into operating leverage, and multiple expansion toward the mid-20s on forward earnings; the $144 low target effectively prices in continued margin compression toward the high-teens and a de-rating to the low-to-mid teens on EPS. With the average target only 2.9% above the current price and the stock at 93% of its 52-week range, the risk/reward is balanced-to-negative near term — the easy money from the recovery has been made, and further upside now requires the Q4 FY26 print to validate the forward EPS of $11.43.
Bulls vs Bears: J Investment Factors
The bear case currently has slightly stronger near-term evidence: gross margin has compressed for four consecutive quarters to 19.89%, Q3 EPS of $1.16 fell short of the prior-year $1.55, and the stock sits at 93% of its 52-week range with only 2.9% upside to the consensus target. The bull case rests on genuine revenue acceleration (+34.6% YoY with sequential gains), a reasonable 19.21x forward PE, and a 10-Buy/0-Sell analyst distribution, but those positives are largely priced in after a 43.18% six-month run. The single most important tension is whether the 34.6% revenue growth can convert into operating leverage — if gross margin stabilizes near 20% and the $11.43 forward EPS materializes, the stock is fairly valued with upside toward $188; if compression continues toward the high-teens, the current price embeds optimistic assumptions and the $144 low target comes into play. Until the Q4 FY26 print resolves that margin question, the risk/reward is balanced-to-negative near term, and the evidence edge goes to the bears on profitability even as the bulls hold the growth and sentiment cards.
Bullish
- Revenue accelerating at 34.6% YoY: Q3 FY26 revenue of $4.076 billion rose 34.57% from $3.029 billion a year earlier, and the sequential climb from $3.295 billion (Q1) to $3.695 billion (Q2) to $4.076 billion (Q3) shows genuine acceleration rather than a soft comp. Infrastructure & Advanced Facilities contributed $3.747 billion of that base, giving the growth a large, backlog-backed core rather than a one-off project spike.
- Forward PE of 19.2x is reasonable: While the trailing PE of 61.87x looks extreme, it is distorted by a near-zero TTM EPS of $0.0163; the forward PE of 19.21x on consensus EPS of $11.43 is a normal multiple for a scaled industrial. PS of 1.48x and EV/Sales of 1.50x sit near the bottom of the multi-year band (versus 5.63x in Q4 FY25), meaning the market is not paying a premium on the revenue line.
- Analyst consensus leans bullish: Of 15 covering analysts, 10 rate Buy and none rate Sell, with a consensus average target of $162.80 (+2.9% from $158.23) and a high target of $188.00 (+18.8%). Recent actions were conviction-holding rather than downgrades — Citigroup reiterated Buy on October 23, KeyBanc reiterated Overweight on October 15, and UBS reiterated Buy on August 10.
- Strong momentum and dip-buying demand: The stock is up 43.18% over six months and 11.43% over one month, with relative strength versus SPY of +13.69 points over one month and +41.05 points over six months. The single-day -7.9% gap on November 5 (from $160.11 to $147.54) was fully recovered within four sessions to $158.23, evidence that buyers step in aggressively on weakness.
Bearish
- Gross margin compressing four straight quarters: Gross margin has fallen from 24.31% in Q4 FY25 to 23.24% in Q1 FY26 to 21.51% in Q2 to 19.89% in Q3 — a clear, unbroken compression trend. The TTM net margin of 2.41% and operating margin of 7.18% are thin for a consulting-led model, so the 34.6% revenue growth is not converting into proportional profit.
- Earnings volatility and quality concerns: Q2 FY26 posted a net loss of $45.9 million (EPS -$0.34) driven by a $49.4 million other-expense hit and a -$45.1 million tax swing, before Q3 rebounded to $136.6 million. This swing shows earnings are highly sensitive to non-operating items, and the Q3 EPS of $1.16 still trails the prior-year Q3 EPS of $1.55 despite 34.6% more revenue.
- Valuation already caught up to Street: The consensus target of $162.80 implies only +2.9% upside, and the stock trades at 93% of its 52-week range ($105.68-$162.00), just 2.3% below the high. EV/EBITDA of 20.75x and P/B of 4.88x are premium-leaning, so the easy re-rating from the recovery has already been captured and further upside requires the Q4 print to validate $11.43 forward EPS.
- Thin balance sheet cushion: Debt-to-equity of 0.744 and a current ratio of 1.301 leave limited buffer, and Q2 FY26 operating cash flow was -$484.1 million on a $501.1 million working-capital drain. With ROE of just 7.97% and ROA of 4.55%, the company is returning capital ($142.2 million buybacks, $42.2 million dividends in Q3) but has little room if margins keep sliding.
J Technical Analysis
Jacobs is in a sustained, powerful uptrend: the stock is at $158.23 versus a 52-week range of $105.68 to $162.00, placing it at roughly 93% of its 52-week range and within about 2.3% of the high. The 1-year change of +3.28% understates the move because it captures the prior-year peak, but the 6-month gain of +43.18% and YTD gain of +16.90% confirm a durable recovery from the lows. Positioning near the top of the range signals momentum leadership rather than deep value, and the stock has already absorbed a -34.77% max drawdown over the trailing year, so the current advance represents a full retracement of that damage.
Short-term momentum is strongly positive and accelerating: the 1-month change of +11.43% and 3-month change of +9.38% both dwarf the 1-year figure, and relative strength versus SPY is +13.69 points over one month and +12.21 points over three months, even as SPY fell -2.26% and -2.83% respectively. The one divergence worth flagging is the 1-year relative strength of -8.99 points, meaning Jacobs lagged the market over twelve months despite crushing it recently — a classic mean-reversion catch-up pattern rather than a breakdown. The single-day -7.9% gap on November 5 (from $160.11 to $147.54) was fully recovered within four sessions to $158.23, which argues the dip was bought aggressively and confirms demand at higher prices.
Key technical levels are clear: resistance sits at the $162.00 52-week high, with the November 2 close of $160.24 marking the immediate ceiling; support rests at the $147.54 post-gap low, with the $105.68 52-week low as the structural floor roughly 33% below spot. A breakout above $162 would signal a fresh leg higher and likely trigger momentum-chasing flows, while a breakdown below $147.54 would put the September consolidation zone near $135-$140 back in play. Beta of 0.669 means the stock is roughly one-third less volatile than the market, which supports larger position sizing on a risk-adjusted basis but also implies the recent +43% six-month move is unusually large for this name and may warrant tighter trailing stops.
Beta
—
—
Max Drawdown
-34.8%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+16.6%
Cumulative gain past year
| Period | J Return | S&P 500 |
|---|---|---|
| 1m | +5.7% | -10.8% |
| 3m | +0.4% | -9.9% |
| 6m | +31.3% | -7.5% |
| 1y | +16.6% | +5.7% |
| ytd | +11.3% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
J Fundamental Analysis
Revenue is growing briskly and the trend is improving: Q3 FY26 revenue of $4.076 billion rose 34.57% year over year versus $3.029 billion in Q3 FY25, and the sequential progression from $3.295 billion (Q1 FY26) to $3.695 billion (Q2) to $4.076 billion (Q3) shows acceleration, not just a favorable comp. Infrastructure & Advanced Facilities at $3.747 billion is the dominant segment, with PA Consulting contributing $329.5 million, so the growth is concentrated in the core engineering and advanced-facilities franchise. The trajectory supports a constructive investment case, though the 34.6% growth rate is far above the ~$11.6 billion consensus revenue estimate for the forward period, implying the market expects normalization rather than continuation at this pace.
Profitability is positive but uneven and margin-compressed: Q3 FY26 net income was $136.6 million on a 19.89% gross margin and 7.03% operating margin, while Q2 FY26 posted a net loss of $45.9 million with a 21.51% gross margin and -2.20% operating margin. Gross margin has drifted from 24.31% in Q4 FY25 to 23.24% in Q1 FY26 to 21.51% in Q2 and 19.89% in Q3 — a clear compression trend that is the single most important fundamental watch item. The TTM net margin of 2.41% and operating margin of 7.18% are thin for a consulting-led model, and the Q2 loss (driven by a $49.4 million other-expense hit and a -$45.1 million tax benefit swing) shows earnings quality is sensitive to non-operating items.
Balance sheet and cash generation are adequate but not fortress-like: debt-to-equity is 0.744, current ratio 1.301, and TTM free cash flow is $644.5 million against a $17.76 billion market cap, a roughly 3.6% FCF yield. Cash flow is highly seasonal and lumpy — Q2 FY26 operating cash flow was -$484.1 million on a $501.1 million working-capital drain, while Q3 rebounded to +$456.1 million operating and +$431.0 million free cash flow — so investors should judge FCF on a trailing basis, not quarter to quarter. ROE of 7.97% and ROA of 4.55% are modest, and with $505 million of debt repaid in Q3 alongside $142.2 million of buybacks and $42.2 million of dividends, the company is returning capital but has limited cushion if margins keep compressing.
Quarterly Revenue
$4.1B
2026-06
Revenue YoY Growth
+34.6%
YoY Comparison
Gross Margin
19.9%
Latest Quarter
Free Cash Flow
$644544000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is J Overvalued?
Because trailing net income is positive (TTM EPS of $0.0163 is barely above zero, but the TTM PE of 61.87x is distorted by a near-zero earnings base), the PE ratio is technically the primary metric but is not analytically useful here; the forward PE of 19.21x is the more meaningful anchor, and the enormous gap between 61.87x trailing and 19.21x forward implies the market expects a dramatic earnings recovery. That expectation is corroborated by consensus EPS of $11.43 versus the current run-rate, so the valuation debate is really about whether that forward number is achievable rather than about the trailing multiple.
Against the sector, Jacobs screens cheap on sales but rich on EBITDA: PS of 1.48x and EV/Sales of 1.50x are low in absolute terms for an engineering and consulting franchise, while EV/EBITDA of 20.75x and P/B of 4.88x are premium-leaning. The PEG ratio of -0.99 is not meaningful given the negative growth denominator, and the 0.86% dividend yield with a 52.7% payout ratio offers minimal income support. The read-through is that the stock is priced for an earnings inflection — cheap on revenue, expensive on current cash earnings — so multiple compression risk is real if the forward EPS bridge disappoints.
Historically, Jacobs has traded in a wide PE band: 12.8x in Q4 FY22, 18.9x-24.7x through 2023-2024, 39.7x in Q4 FY25, and 61.9x now, while PS has ranged from roughly 2.95x (Q4 FY22) to 5.63x (Q4 FY25) and now sits at 1.48x. The PS multiple is near the bottom of its multi-year band even as the PE is near the top, a direct consequence of the revenue surge outpacing earnings — which suggests the market is not yet paying up on sales but is demanding proof on margins. If gross margin stabilizes near 20% and the forward EPS materializes, the 19.21x forward PE is reasonable for an industrial; if margin compression continues toward the high-teens, the current price embeds optimistic assumptions.
PE
61.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~42x
vs. Industry Avg
27.6x
Industry PE ~27.6x*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin erosion and earnings quality. Gross margin has declined every quarter for a year, from 24.31% in Q4 FY25 to 19.89% in Q3 FY26, and the TTM net margin of just 2.41% means a small cost overrun can wipe out profit — as demonstrated by the Q2 FY26 net loss of $45.9 million driven by a $49.4 million other-expense hit and a -$45.1 million tax swing. Cash flow is highly seasonal and lumpy, with Q2 FY26 operating cash flow of -$484.1 million on a $501.1 million working-capital drain, and debt-to-equity of 0.744 with a current ratio of 1.301 leaves limited cushion if margins keep compressing. Revenue is also concentrated: Infrastructure & Advanced Facilities at $3.747 billion dwarfs PA Consulting's $329.5 million, so any slowdown in public infrastructure or advanced-facilities spending hits the core directly.
Market and competitive risks are dominated by valuation compression and the stock's extended positioning. At $158.23 the shares sit at 93% of the 52-week range and just 2.3% below the $162.00 high, with a consensus target of $162.80 offering only +2.9% upside — the recovery trade is largely done. EV/EBITDA of 20.75x and P/B of 4.88x are premium-leaning for an engineering and construction firm, and the 61.87x trailing PE versus 19.21x forward embeds a dramatic earnings recovery that must be delivered. Beta of 0.669 dampens market-wide shocks, but the stock's 1-year relative strength of -8.99 points versus SPY shows it can lag even in a rising market, and the wide $144-$188 analyst range with 6 of 15 Holds signals genuine disagreement that can amplify volatility around earnings.
A worst-case scenario would combine continued gross-margin compression toward the high-teens with a Q4 FY26 EPS miss against the $11.43 consensus, triggering analyst downgrades from the current 10-Buy bloc and a de-rating toward the low-to-mid teens on forward earnings. In that chain, the stock would likely retest the $144.00 analyst low target (-9.0% from spot) and, in a broader risk-off move, the September consolidation zone near $135-$140, with the $105.68 52-week low as the structural floor roughly 33% below the current price. Given the -34.77% max drawdown already experienced over the trailing year, an investor could realistically lose 9% to 15% in a margin-disappointment scenario and up to roughly 33% in a severe de-rating that revisits the 52-week low.
FAQ
The most severe risk is margin erosion: gross margin has fallen from 24.31% in Q4 FY25 to 19.89% in Q3 FY26, and with TTM net margin at only 2.41%, a further slide toward the high-teens would invalidate the $11.43 forward EPS and force a de-rating toward the $144 low target. Second is earnings quality and volatility — Q2 FY26 produced a net loss of $45.9 million on a $49.4 million other-expense hit and a -$45.1 million tax swing, showing small non-operating items can swing results sharply. Third is balance-sheet and cash-flow risk: debt-to-equity of 0.744, a current ratio of 1.301, and a Q2 FY26 operating cash flow of -$484.1 million on a $501.1 million working-capital drain leave limited cushion if margins keep compressing. Fourth is valuation and positioning risk: at 93% of the 52-week range with only +2.9% upside to consensus, the recovery is largely priced in, and the 1-year relative strength of -8.99 points versus SPY shows the stock can lag even in rising markets. Ranked by severity: margin compression first, then earnings volatility, then balance-sheet flexibility, then valuation compression.
The 12-month outlook splits into three scenarios. The base case carries 50% probability with a $155-$168 range, assuming gross margin stabilizes between 19.5% and 21%, forward EPS lands near the $11.43 consensus, and the multiple holds at 19x-21x, leaving the stock grinding around the $162.80 average target with the $162.00 52-week high as resistance. The bull case at 25% probability targets $175-$188, requiring gross margin at or above 20%, confirmation of forward EPS, and multiple expansion toward the mid-20s on forward earnings, with Infrastructure & Advanced Facilities backlog conversion and PA Consulting's $329.5 million contribution as catalysts. The bear case at 25% probability targets $130-$144, driven by gross margin breaking below 19%, a Q4 FY26 EPS miss versus $11.43, and downgrades from the 10-Buy bloc, retesting the $144 analyst low and the $135-$140 consolidation zone. The base case is most likely, and its key assumption is that the four-quarter margin compression troughs rather than continues.
The valuation is bifurcated rather than simply cheap or expensive. On sales, J looks inexpensive: PS of 1.48x and EV/Sales of 1.50x sit near the bottom of a multi-year band that ranged up to 5.63x in Q4 FY25, reflecting revenue growth that has outpaced earnings. On earnings and book value, it looks premium-leaning: EV/EBITDA of 20.75x and P/B of 4.88x are rich for an engineering and construction firm, and the 61.87x trailing PE versus 19.21x forward embeds a dramatic EPS recovery to $11.43 from a TTM EPS of just $0.0163. The market is therefore paying for an earnings inflection, not current profitability — the forward multiple is reasonable only if gross margin stabilizes near 20%, and the PEG ratio of -0.99 is not meaningful given the negative growth denominator. Net, the stock is fairly valued on forward earnings, cheap on sales, and expensive on current cash earnings, with the 0.86% dividend yield and 52.7% payout ratio offering little valuation support.
From a risk/reward standpoint, J is a reasonable but not compelling buy at $158.23: the consensus target of $162.80 offers only +2.9% upside, while the $144.00 low target implies -9.0% downside, so the near-term skew is roughly symmetric and the stock already sits at 93% of its 52-week range. The quality case is real — revenue grew 34.6% YoY to $4.076 billion, 10 of 15 analysts rate Buy with zero Sells, TTM free cash flow of $644.5 million is a ~3.6% yield, and beta of 0.669 limits volatility. The catch is profitability: gross margin has compressed four straight quarters to 19.89%, Q3 EPS of $1.16 trails the prior-year $1.55, and TTM net margin is just 2.41%, so the 19.21x forward PE depends on an EPS recovery to $11.43 that has not yet shown up in margins. It is a better buy on pullbacks toward the $144-$147 support zone than at the top of the range, and best suited to investors with a 12-24 month horizon who can tolerate an earnings-driven de-rating risk of 9-15% if the Q4 FY26 print disappoints.
J is better suited to a medium-to-long-term hold than to short-term trading, though it is not a classic buy-and-forget compounder. The growth stage is a cyclical recovery: revenue is accelerating at 34.6% YoY, but TTM net margin of 2.41% and ROE of 7.97% mean earnings visibility is low and quarterly prints can swing sharply, as the Q2 FY26 net loss of $45.9 million and the -7.9% single-day gap on November 5 both demonstrate. Volatility is moderate — beta of 0.669 is roughly one-third below the market — but the -34.77% max drawdown over the trailing year shows the downside can be material, and the 0.86% dividend yield with a 52.7% payout ratio provides minimal income support for a long-term income thesis. Earnings visibility is the weak link: the entire 19.21x forward PE rests on a $11.43 EPS recovery that has not yet appeared in gross margins, so the thesis must be re-underwritten each quarter. A concrete suggested minimum holding period is 12-18 months, spanning at least two to three quarterly prints to confirm the margin trough, with position sizing kept modest and entries favored on pullbacks toward the $144-$147 support zone rather than near the $162 high.

